Gilead Sciences: PharmaVitae Profile

Introduction

This analysis examines the historical and forecast performance for Gilead in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

Features and benefits

Gain insight into Gilead's strategic outlook across the next 6 years

Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source

Highlights

Strategic insight into the prospects for Gilead over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.

Your key questions answered

• Benchmark Gilead's performance against key rivals in the prescription pharmaceutical sector
• Assess the effects of the patent expiry of one of the components of Atripla on the company
• See how the launch of two new products, Truvada + rilpivirine and the Quad pill, will generate new growth for the company

Please note: this is delivered as a Zip file.